What are the effects of various oral maintenance dosages of L-carnitine on all-cause mortality and cardiovascular morbidities in patients with acute myocardial infarction?
L-Carnitine, a meta-analysis in 3108 participants (BMC Cardiovasc Disord 2014, PMID 25044037) — no significant differences were found between 2 g and 6 g doses for heart failure (RR = 0.53, P = 0.10), unstable angina (RR = 0.90, P = 0.71), or myocardial reinfarction (RR = 0.74, P = 0.50). Scope: 3108 participants, and the abstract states no limitations.
Source: BMC Cardiovasc Disord 2014, PMID 25044037 ↗ · Research map · How Magellan grades evidence · evidence confidence: high
BMC Cardiovasc Disord · 2014 · PMID 25044037 · DOI 10.1186/1471-2261-14-88
Daily L-carnitine doses above or below 3g do not offer additional benefits for mortality or cardiovascular events after a heart attack.
The question
What are the effects of various oral maintenance dosages of L-carnitine on all-cause mortality and cardiovascular morbidities in patients with acute myocardial infarction?
What they tested
Higher doses of L-carnitine supplementation may not provide additional therapeutic benefits due to strict homeostatic regulation of plasma L-carnitine concentrations.
How they did it
A meta-analysis of five controlled trials (n = 3108) was conducted after a systematic review of PubMed, EMBASE, and the Cochrane Library up to November 2013. The analysis determined the effects of L-carnitine on all-cause mortality and cardiovascular morbidities in acute MI patients.
What they found
There were no significant differences in the effects of 2 g, 3 g, 4 g, and 6 g daily oral L-carnitine doses on all-cause mortality (RR = 0.77, 95% CI [0.57-1.03], P = 0.08). A statistically insignificant trend favored the 3 g dose (RR = 0.48) over the 2 g dose (RR = 0.62), which was favored over the 4 g and 6 g doses (RR = 0.78, 0.78). No significant differences were found between 2 g and 6 g doses for heart failure (RR = 0.53, P = 0.10), unstable angina (RR = 0.90, P = 0.71), or myocardial reinfarction (RR = 0.74, P = 0.50).
| 3 g | 0.48 | |
|---|---|---|
| 2 g | 0.62 | |
| 4 g | 0.78 | |
| 6 g | 0.78 |
Risk ratios for all-cause mortality across different daily oral L-carnitine maintenance dosages, showing a trend favoring the 3g dose.
What it means
There appears to be no significant marginal benefit for oral L-carnitine maintenance doses greater or less than 3 g per day in terms of all-cause mortality, heart failure, unstable angina, or myocardial reinfarction in acute MI patients.
Limitations
The abstract does not explicitly state limitations of the study.
Where the published abstract does not list limitations, we say so rather than inventing them. Read the full paper on PubMed before drawing conclusions.
The paper at a glance
| Magellan’s evidence label | fatty-acid mitochondrial shuttle (our label for this citation — see PubMed for the paper’s own title and authors) |
|---|---|
| Journal | BMC Cardiovasc Disord |
| Year | 2014 |
| PMID | 25044037 ↗ |
| DOI | 10.1186/1471-2261-14-88 ↗ |
| Topic | Cardiovascular & vascular aging |
Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗
Where Magellan uses this paper
This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.
L-Carnitine
Older and mostly small randomized trials, pooled in meta-analyses, suggest that L-carnitine given around the time of an acute myocardial infarction is associated with reduced all-cause mortality, ventricular arrhythmias and angina, and with attenuated left-ventricular dilation and smaller infarct size, effects…
L-carnitine is a naturally occurring, vitamin-like compound synthesized from the amino acids lysine and…
Research describes the compound or intervention studied. It is not a claim about any specific product.
Molecules & mechanisms in this paper
Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.
Cite this page
These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.
Magellan Longevity. (2026). What are the effects of various oral maintenance dosages of L-carnitine on all-cause mortality and cardiovascular morbidities in patients with acute myocardial infarction? [Plain-English summary of BMC Cardiovasc Disord 2014, PMID 25044037, DOI 10.1186/1471-2261-14-88]. Magellan Longevity. https://magellanlongevity.com/study/s135.html@misc{magellan_s135,
title = {What are the effects of various oral maintenance dosages of L-carnitine on all-cause mortality and cardiovascular morbidities in patients with acute myocardial infarction?},
author = {{Magellan Longevity}},
year = {2026},
howpublished = {\url{https://magellanlongevity.com/study/s135.html}},
note = {Plain-English summary of PubMed PMID 25044037; DOI 10.1186/1471-2261-14-88; BMC Cardiovasc Disord 2014. Reviewed by Gabriel Radu, DO},
urldate = {2026-08-11}
}https://magellanlongevity.com/study/s135.htmlRelated studies in the Magellan library
- L-carnitine in the secondary prevention of cardiovascular diseaseMayo Clin Proc · 2013 · PMID 23597877
- Is Acetyl-l-carnitine (ALC) clinically effective in treating people with dementia?Cochrane Database Syst Rev · 2003 · PMID 12804452
- Cardioprotection and lifespan extension by the natural polyamine spermidineNature Medicine · 2016 · PMID 27841876
- Ubiquinol in patients with severe sepsis or septic shockCrit Care · 2015 · PMID 26130237
- Regulation of structural and functional synapse density by L-threonate through intraneuronal…Neuropharmacology · 2016 · PMID 27178134
- Mechanisms and applications of the anti-inflammatory effects of photobiomodulationAIMS Biophysics · 2017 · PMID 28748217
All 67 Magellan summaries on cardiovascular & vascular aging →
Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →